CJC-1295 + GHRP-2

1 Identity

Fixed-ratio two-component article: a 30-residue C-terminally amidated GHRH analogue bearing a 3-maleimidopropionyl group on the Lys30 side chain, co-lyophilized with a synthetic GHRP-class hexapeptide. One component carries a thiol-reactive electrophile, and that single fact sets the handling and the shelf life of the whole article. The title is ambiguous as sold and this record resolves it one way: CJC-1295 here means the DAC-bearing maleimide conjugate, CAS 446262-90-4. Trade usage also applies the bare name to Modified GRF (1-29), which is 279.296 Da lighter and carries no maleimide; that article blended with GHRP-2 is a separate record in this catalog and not a variant of this one.

Sequence

Stated per component and cross-referenced to the component records. CJC-1295 (DAC:GRF) is the tetrasubstituted GHRH(1-29) core extended by Lys30 bearing N-epsilon-3-maleimidopropionyl, amidated at the C-terminus - thirty residues, not twenty-nine, and the residue count is itself an identity check. GHRP-2 is H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2, six residues, C-terminal primary amide. GHRP-2 contains no cysteine, so the conjugate's thiol-reactive group has no reaction partner among the residues sharing this vial; that is a finding about this composition, derived from the two residue sets, and it is re-derived rather than inherited for any other blend built on the same conjugate.

Molecular formula

Stated per component. A mixture has no combined formula and none is written. CJC-1295 C165H269N47O46. GHRP-2 C45H55N9O6 as the free base and C47H56F3N9O8 as the mono-trifluoroacetate, commonly supplied as the acetate. Counterion is determined and reported per component: a single blend counterion figure is uninterpretable where one component is routinely a TFA salt at a high counterion mass fraction and the other is not.

Average mass

Per component, on IUPAC 2021 abridged conventional atomic weights: CJC-1295 3,647.250 Da; GHRP-2 817.992 Da. AT A nominal 5 mg + 5 mg fill, 10 mg total, the 1.0 : 1.0 mass ratio is a molar ratio of 1.00 : 4.46 - 1.37090 against 6.11253 micromol - so a document that reads the mass ratio as a molar ratio is wrong on its face. The 279.296 Da separation from Modified GRF (1-29) is the acceptance-critical figure on this record: it is 7.7 percent of the conjugate's mass, which no instrument on the panel can miss and no certificate has an excuse for omitting.

Monoisotopic mass

Per component. CJC-1295 3,645.0155 neutral, observed only multiply charged, [M+3H]3+ 1,216.0124 and [M+4H]4+ 912.2612, reported as a deconvoluted neutral rather than as a single-ion match. GHRP-2 817.4275, [M+H]+ 818.4348. The maleimide hydrolysis product sits at +18.011 Da on the conjugate and is a specified degradant with its own limit, not an unknown. A single blend molecular weight is never printed; a mixture does not have one.

Salt / variant note

Confusables on this article run in two families, one on each side of the vial. (1) the DAC fork, the defining ambiguity: CJC-1295 (DAC:GRF) at 3,647.250 against Modified GRF (1-29) at 3,367.954, the two circulating under the same two-word name in different listings. (2) the hydrolyzed conjugate at +18.011 Da, which is not a different product but a degraded lot of this one, and invisible to inspection. (3) Sermorelin at 3,357.933, which carries one sulfur, and (D-Ala2)-GRF(1-29) amide, both circulating in this category. (4) the secretagogue fork on the hexapeptide side: GHRP-6 873.032, hexarelin 887.06, ipamorelin 711.868. (5) Counterion, measured per component. (6) Ratio: 5 mg + 5 mg is a stated nominal used for the arithmetic above, and no ratio is standard across listings.

2 Class & testing panel

Form

Fixed-ratio blend

Testing panel

P3 — panel definitionfor both components, run per component and in union rather than once on the mixed vial. The panel is engaged twice for stereochemistry - D-Ala2 in CJC-1295; D-Ala1, D-2-Nal2 and D-Phe5 in GHRP-2, with 2-naphthylalanine non-proteinogenic - so a chiral method is mandatory and each component is judged against its own expected D-content. The maleimide adds one test not on the standard P3 sheet and required here: intact maleimide content, determined against the ring-opened maleamic acid product, because ring hydrolysis proceeds with no visible change to the cake. A single pass over the mixed vial would return a pooled purity, a pooled chirality figure and a pooled content figure, none of them attributable to either component, so net content and the measured ratio are per-component determinations

3 Primary sources & evidence

The index reports the design and provenance of the literature, not a conclusion about effect.

What follows reports study design and provenance, not a conclusion about effect. Published literature exists for each component, sits on that component's own record in this catalog, and is cross-referenced here rather than restated. Phase 1 in healthy adults: the CJC-1295 component's record carries sponsor-run phase 1 work published in the Journal of Clinical Endocrinology and Metabolism in 2006, by Teichman and colleagues; no phase 2 or phase 3 result was published, and development of the conjugate was discontinued in 2006. Human pharmacology: the GHRP-2 component's record carries human literature indexed there by identifier. Combination literature: none identified. No published study of this fixed two-component combination at any ratio was identified, and no consensus specification for the combination was identified; that is a statement about the published record and not a conclusion about either component.

4 Storage & specification

Storage

Co-lyophilized solid in a Type I amber borosilicate serum vial, sealed under nitrogen, desiccated, carrying the conjugate's own label statement: the material is not to be brought into contact with any free thiol or reducing agent. Store at -20 degrees C plus or minus 5 degrees C, protected from light. Amber glass or a foil overwrap is required rather than precautionary, the GHRP-2 indole and naphthalene rings being photolabile. Desiccation is a specification and not housekeeping: maleimide ring hydrolysis to the maleamic acid is water-mediated, so residual water in the cake is a reaction substrate, and in aqueous solution above pH 7.5 that hydrolysis is rapid and leaves an unreactive form with no visible change to the material. The article is therefore specified, filled and held dry. Non-sterile laboratory chemical, no sterility claim, not an injection presentation.

Shelf life

Twelve months at -20 degrees C plus or minus 5 degrees C, desiccated and protected from light, provisional. The interval is deliberately half the class default and is taken from CJC-1295, whose retest-limiting attribute is solid-state maleimide ring hydrolysis rather than peptide-backbone degradation, set against GHRP-2's provisional 24 months. Taking the shorter of the two component intervals is the rule for every blend, and here the two differ by a factor of two, so the rule has a visible consequence. The blend runs its own stability protocol and inherits no component study, with a mandatory 6-month interim pull on the first three lots. Trended attributes: per-component net content, the measured ratio, intact maleimide against the ring-opened species, aspartimide at Asp3 and Asp25, indole oxidation, water, counterion and any new peak above 0.10 percent.